Impact of lung diseases on morbidity and mortality after transcatheter aortic valve implantation: Insights from spirometry and body plethysmography: Valvular and Congenital Heart Disease

• Published in: The American heart journal 2015-10, Vol.170 (4), p.837-842.e1
• Main Authors: Gotzmann, Michael, Knoop, Heiko, Ewers, Aydan, Muegge, Andreas, Walther, Jorg W
• Format: Article
• Language: English
• ISSN: 0002-8703
• DOI: 10.1016/j.ahj.2015.07.011

Background The study aims to determine the impact of different lung diseases on morbidity and mortality after transcatheter aortic valve implantation (TAVI). Methods Transcatheter aortic valve implantation was performed transfemoral or transaxillary with CoreValve prosthesis or Edwards SAPIEN prosthesis in patients with symptomatic severe aortic valve stenosis and high surgical risk. Examinations comprised spirometry, body plethysmography echocardiography, and x-ray before TAVI. The primary study end point was death from any cause after TAVI. Results During follow-up of 750 plus or minus 538 days, 63 of 212 patients died. Logistic European System for Cardiac Operative Risk Evaluation (hazard risk [HR] 1.032, P < .001), aortic mean gradient (HR 0.96, P < .001), chronic obstructive pulmonary disease (COPD; each degree of COPD: HR 1.436, P = .001), restrictive ventilatory disease (HR 2.252, P = .002), oxygen dependency (HR 3.291, P = .004), and noninvasive ventilation (HR 3.799, P = .005) were independent predictors of long-term mortality. Restrictive ventilatory disease was associated with lower left ventricular ejection fraction, higher B-type natriuretic peptide levels, and pulmonary edema. Conclusion In patients undergoing TAVI, lung diseases are an independent predictor of all-cause mortality. In particular, oxygen dependency patients and patients with severe COPD and noninvasive ventilation indicate a dismal prognosis. Transcatheter aortic valve implantation seems to have a dubious prognostic benefit in these patients.